Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 15/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30922851 | 0.88 | MAPK1 (0.50) | ALDH1A1MAPTLMNARAF1HPGD | |
| SCHEMBL4949648 | 0.84 | MAPT (0.62) | ALDH1A1MAPTLMNARAF1HPGD | |
| SCHEMBL30178231 | 0.83 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL13301370 | 0.83 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL541479 | 0.82 | ALDH1A1 (0.68) | ALDH1A1MAPTLMNARAF1HPGD | |
| SCHEMBL7010553 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL31254041 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAMAPK1VCAM1 | |
| SCHEMBL31254046 | 0.81 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNAMAPK1VCAM1 | |
| SCHEMBL21824111 | 0.81 | MAPT (0.44) | ALDH1A1MAPTLMNAHPGDMAPK1 | |
| SCHEMBL6831160 | 0.81 | MAPT (0.55) | ALDH1A1MAPTLMNAHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372380-B2 | In vivo imaging of sulfotransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372380-B2 | In vivo imaging of sulfotransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372380-B2 | In vivo imaging of sulfotransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100135906-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-06-03 | — | — | US | disclosed |
| US-20100135906-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-06-03 | — | — | US | disclosed |
| US-20100135906-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-06-03 | — | — | US | disclosed |
| EP-2171478-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | The Regents Of The University Of California (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008121407-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121407-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-1992004350-A1 | OXYGENATED QUINOXALINES | THE UPJOHN COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135906-A1 | IN VIVO IMAGING OF SULFOTRANSFERASES | SULT1A1, SULT2A1, TPST2 | ALDH1A1 232/4885MAPT 1122/4885LMNA 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.